Literature DB >> 11590540

Tuberculosis and HIV infection: epidemiology, immunology, and treatment.

N W Schluger1, J Burzynski.   

Abstract

Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all patients with tuberculosis have concomitant HIV infection. In urban centers in developed nations, HIV co-infection may also be quite common. Treatment of latent tuberculosis infection in persons with HIV is successful in preventing many cases of active disease, and newer ultra-short course regimens, such as those consisting of 2 months of rifampin and pyrazinamide, should aid in this effort. Diagnosis and treatment of active tuberculosis in HIV-infected patients may be difficult. Although treatment of active tuberculosis is generally successful in patients with HIV, drug interactions between anti-tuberculosis medications and antiretrovirals often complicate the matter, and expert guidance should be sought for proper management.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590540     DOI: 10.1310/TUNH-UAKU-N0E4-1PXF

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  4 in total

1.  A case of tuberculosis cutis orificialis with perianal involvement.

Authors:  Se Rim Choi; Jin Ki Kim; Dong Hyun Kim; Moon Soo Yoon
Journal:  Ann Dermatol       Date:  2009-11-30       Impact factor: 1.444

2.  Tuberculosis rates among HIV-infected persons in New York City, 2001-2005.

Authors:  Lisa Trieu; Jiehui Li; David B Hanna; Tiffany G Harris
Journal:  Am J Public Health       Date:  2010-04-15       Impact factor: 9.308

3.  Community based interventions for the prevention and control of tuberculosis.

Authors:  Ahmed Arshad; Rehana A Salam; Zohra S Lassi; Jai K Das; Imama Naqvi; Zulfiqar A Bhutta
Journal:  Infect Dis Poverty       Date:  2014-08-01       Impact factor: 4.520

4.  Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA.

Authors:  Lisa Trieu; Douglas C Proops; Shama D Ahuja
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.